AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

852.792

-10.393-1.20%

Number of Gainers:3

Number of Losers:16

Number of Flat:27

PE:- -

High:863.169

Open:863.169

Low:849.902

Close:863.185

Loading ...

CSL shares: Buy, sell or hold in 2025?

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

Dimerix Ltd - Loss for Half-Year Attributable a$12.9 Mln

THOMSON REUTERS

BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 Million

Here are the top 10 ASX 200 shares today

Actinogen reports busy 6 months as development of Xanamem molecule ramps up

The Market Herald

Actinogen Medical Ltd - Hy Net Loss Attributable a$8.2 Mln

THOMSON REUTERS

3 ASX Growth Stocks With High Insider Ownership To Watch

Simply Wall St.

Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%

MT Newswires Live

Polynovo H1 Net Income AUD 3.3 Million

THOMSON REUTERS

Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA

BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation

DR. Gregory George Md Phd Joins Mesoblast Board

THOMSON REUTERS

Dr. Gregory George MD PhD Joins Mesoblast Board

Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":852.79175,"timestamp":1741302839463,"preClose":863.1849,"halted":0,"volume":10653706,"delay":0,"changeRate":-0.01204,"change":-10.393127,"amount":77482244,"amplitude":0.01537,"prevYearClose":936.801,"fiveDayClose":863.841,"twentyDayClose":904.086,"turnoverRate":0.000288,"marketCap":137156045391,"floatMarketCap":133889912508.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":863.16907,"amplitude":0.01537,"preClose":863.1849,"low":849.90155,"latestPrice":852.79175,"volume":10653706,"delay":0,"open":863.16907,"prevYearClose":936.801,"prevWeekClose":863.841,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":863.841,"twentyDayClose":904.086,"sixtyDayClose":929.134,"secType":"PLATE","market":"AU","turnoverRate":0.000288,"marketCap":137156045391,"floatMarketCap":133889912508.5,"timestamp":1741302839463,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":3,"down":16,"flat":27},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514080272","title":"CSL shares: Buy, sell or hold in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514080272","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514080272?lang=en_us&edition=fundamental","pubTime":"2025-02-25 10:28","pubTimestamp":1740450494,"startTime":"0","endTime":"0","summary":"CSL Ltd  shares are up 0.3% at $261.87 today, shaking off the broader market sell-down. This sees the company with a market cap of almost $127 billion, making it the third largest stock on the ASX. Over the past year, however, shares in the S&P/ASX 200 Index biotech stock have trailed the benchmark, sliding 9%, while the ASX 200 has gained 8%. Though those losses were somewhat moderated by the $4.25 a share in unfranked dividends CSL paid out  over the year. But with CSL shares continuing to struggle in 2025, is the biotech stock one to buy, sell, or hold onto?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/25/csl-shares-buy-sell-or-hold-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","BK4086","LU1169590202.USD","BK7508","XJO.AU","BK7501","BK7067","BK7511","SG9999004303.SGD","CSL","SGXZ23171101.USD","LU0728928796.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2514903897","title":"Why has this ASX 200 healthcare stock crashed 24% in 2 days?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514903897","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514903897?lang=en_us&edition=fundamental","pubTime":"2025-02-25 10:06","pubTimestamp":1740449168,"startTime":"0","endTime":"0","summary":"The Polynovo Ltd  share price is having another tough session. At the time of writing, the ASX 200 healthcare stock is down 16.5% to $1.49. This means that the medical device company's shares are now down 24% over the past two trading sessions. Why is this ASX 200 healthcare stock crashing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/25/why-has-this-asx-200-healthcare-stock-crashed-24-in-2-days/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7126","PNV.AU","BK7508"],"gpt_icon":1},{"id":"2514704820","title":"Dimerix Ltd -  Loss for Half-Year Attributable a$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704820?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:08","pubTimestamp":1740434926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2513971631","title":"BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2513971631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513971631?lang=en_us&edition=fundamental","pubTime":"2025-02-24 15:19","pubTimestamp":1740381559,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Posts HY Net Loss Attributable A$8.2 MillionFeb 24 (Reuters) - Actinogen Medical Ltd ACW.AX:ACTINOGEN MEDICAL LTD - HY NET LOSS ATTRIBUTABLE A$8.2 MILLIONFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2513134277","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2513134277","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513134277?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:14","pubTimestamp":1740377653,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day losing s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/24/here-are-the-top-10-asx-200-shares-today-24-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA.AU","ING.AU","ANZ.AU","BK7089","XJO.AU","NEU.AU","BK7078","BK7141","BK7035","BK7096","BK7148","BK7135","SEK.AU","SGR.AU","NHF.AU","BK7505","EVT.AU","APA.AU","BK7511","ALL.AU","BK7002","BK7508"],"gpt_icon":0},{"id":"2513173697","title":"Actinogen reports busy 6 months as development of Xanamem molecule ramps up","url":"https://stock-news.laohu8.com/highlight/detail?id=2513173697","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513173697?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:59","pubTimestamp":1740376740,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd  said its net loss after tax for the six months to December 2024 decreased by 29% to $8,168,979 – compared to $11,556,659 in the HY24 – largely based on the ramping up of development activity for lead molecule Xanamem, intended for treatment of Alzheimer’s disease and depression.Research and development costs – mainly relating to clinical trials – accounted for the main expenditure item, with these costs being $4.58 million.Actinogen reported a busy and successful year in terms of these trials, including ongoing progress in screening and enrolment for its XanaMIA phase 2b/3 Alzheimer’s disease  trial, and positive findings yielded from its completed XanaCIDD phase 2a major depressive disorder  trial.Results from the latter included positive findings on depressive symptoms – with this supporting the theory that controlling cortisol can have clinical benefits.The material provided in this article is for information only and should not be treated as investment advice","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/actinogen-reports-busy-6-months-as-development-of-xanamem-molecule-ramps-up-2025-02-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK4218","INN","BK4181","ACW.AU","BK7067"],"gpt_icon":0},{"id":"2513794138","title":"Actinogen Medical Ltd - Hy Net Loss Attributable a$8.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2513794138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513794138?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:29","pubTimestamp":1740371351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2513923407","title":"3 ASX Growth Stocks With High Insider Ownership To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2513923407","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513923407?lang=en_us&edition=fundamental","pubTime":"2025-02-24 12:02","pubTimestamp":1740369763,"startTime":"0","endTime":"0","summary":"As the Australian market braces for a potential downturn, with ASX 200 futures indicating a significant decline following Wall Street's recent struggles, investors are keenly watching how local companies navigate these turbulent times. In such an environment, growth stocks with high insider ownership can be particularly appealing, as they often signal confidence from those closest to the company's operations and strategy.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 99 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: MA Financial Group Limited, with a market cap of A$1.33 billion, operates in Australia offering a range of financial services through its subsidiaries.Operations: MA Financial Group Limited generates revenue through its subsidiaries by providing a variety of financial services within Australia.MA Financial Group is poised for significant earnings growth, with forecasts indicatin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-growth-stocks-high-040243085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","EMR.AU","FND.AU","LU0107464264.USD","LU0820562030.AUD","MM8.AU","XKO.AU","LU1623119135.USD","LU1712237335.SGD","LU0106261372.USD","MAF.AU","LU0094547139.USD","LU1917777945.USD","LU0417517546.SGD","NWF.AU","LU2063271972.USD","BK4106","BK7104","IE00BYQQ9H92.USD","LU0942090050.USD","PLT.AU","LU2720916845.USD","SG9999001424.SGD","XAO.AU","LU0786609619.USD","LU0689472784.USD","IE00BJJMRX11.SGD","LU0234572021.USD","CUV.AU","IE0004091025.USD","MA","3DP.AU","AVA.AU","IE00B775H168.HKD","BK7043","LU0823421416.USD","LU0109392836.USD","LU0964807845.USD","SKS.AU","BK7096","LU0823421333.USD","UNI.AU","FLT.AU","LU2756315318.SGD","LU1551013425.SGD","XJO.AU","BK7508","ACR.AU","IE0009356076.USD","LU1551013342.USD"],"gpt_icon":0},{"id":"2513799917","title":"Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513799917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513799917?lang=en_us&edition=fundamental","pubTime":"2025-02-24 11:26","pubTimestamp":1740367584,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received rare pediatric disease designation from the US Food and Drug Administration for its neurodevelopmental disorder drug candidate, NNZ-2591, in each of Pitt Hopkins syndrome and Angelman syndrome, according to a Monday filing with the Australian bourse.NNZ-2591 previously received the same designation for Phelan-McDermid syndrome.The Australian pharmaceutical company said it \"may be awarded a priority review voucher  if the Rare Pediatric Disease PRV program is reauthorized by the US Congress and NNZ-2591 receives marketing authorization for any of these indications.\"If awarded, a PRV can be used to obtain a priority review for a different product or sold to another sponsor.Neuren Pharmaceuticals' shares were up past 6% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XKO.AU","NEU.AU","XAO.AU","XJO.AU","BK7096"],"gpt_icon":0},{"id":"2513935017","title":"Polynovo H1 Net Income AUD 3.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2513935017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513935017?lang=en_us&edition=fundamental","pubTime":"2025-02-24 10:18","pubTimestamp":1740363516,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nPLXAA51D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PNV.AU","BK7508","BK7126"],"gpt_icon":0},{"id":"2513266798","title":"Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266798?lang=en_us&edition=fundamental","pubTime":"2025-02-24 10:02","pubTimestamp":1740362534,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  received centralized Human Research Ethics Committee approval in Australia for its pivotal PARA_OA_012 phase three clinical trial, which will study the safety and efficacy of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis, according to a Monday Australian bourse filing.It said the recruitment of the first subject for the trial is on target and first participant dosing is expected in the second quarter, the filing said.The approval allows the trial to proceed across multiple key clinical trial sites in Australia, the filing said.The first trial sites to be activated are expected to be located in Victoria.The firm's shares rose 2% in early trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","XJO.AU","BK7067","XAO.AU","BK7508","XKO.AU"],"gpt_icon":0},{"id":"2513762069","title":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513762069","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513762069?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:21","pubTimestamp":1740360101,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDAFeb 24 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:NEUREN RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDAFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2513976255","title":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513976255?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:05","pubTimestamp":1740359124,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7** Stock on track for its second consecutive session of gains, if trend holds** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration ** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren ** NNZ-2591 used for treatment of any traumatic brain injury    ** Stock has risen 11.6% so far this year, as of 0054 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF00W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2513667287","title":"DR. Gregory George Md Phd Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513667287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513667287?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nTUA39FYLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2513769339","title":"Dr. Gregory George MD PhD Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513769339","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513769339?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353580,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 23, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors.Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization.Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, “Greg’s unique operational skills and insights will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.”Mesoblast is committed to developing additional cell therapies for distinct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-gregory-george-md-phd-233300998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4196","BK4150","BK4006","BK4575","BK7501","MSB.AU","MD","BK7508","MESO","BK4139","MSC","BK7067","MSB","MMAT","BK4141"],"gpt_icon":0},{"id":"2513630167","title":"Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513630167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513630167?lang=en_us&edition=fundamental","pubTime":"2025-02-24 06:20","pubTimestamp":1740349213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":9,"totalSize":151}]}}